{"corpus_id":275406579,"paper_sha":"2769f801b020fff7aa60cd4adf5443658c780091","doi":"10.1016/s0140-6736(24)02263-3","arxiv_id":null,"pmid":39798984,"pmcid":null,"mag_id":null,"dblp_id":null,"acl_id":null,"title":"Axial spondyloarthritis.","year":2025,"publication_date":"2025-01-01","venue":"The Lancet","journal":{"name":"Lancet","pages":"\n          159-172\n        ","volume":"405 10473"},"journal_issn":null,"journal_title":null,"publication_types":["Review","JournalArticle"],"pubmed_pub_types":["Journal Article","Review","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine"],"reference_count":139,"citation_count":26,"influential_citation_count":1,"is_open_access":false,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Axial Spondyloarthritis","mj":true,"qs":[{"q":"diagnosis","mj":false,"ui":"Q000175"},{"q":"therapy","mj":false,"ui":"Q000628"}],"ui":"D000089183"},{"d":"Anti-Inflammatory Agents, Non-Steroidal","mj":false,"qs":[{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D000894"},{"d":"Sacroiliac Joint","mj":false,"qs":[{"q":"pathology","mj":false,"ui":"Q000473"},{"q":"diagnostic imaging","mj":false,"ui":"Q000000981"}],"ui":"D012446"},{"d":"Magnetic Resonance Imaging","mj":false,"ui":"D008279"},{"d":"HLA-B27 Antigen","mj":false,"ui":"D015796"}],"chemicals":[{"n":"Anti-Inflammatory Agents, Non-Steroidal","ui":"D000894","reg":"0"},{"n":"HLA-B27 Antigen","ui":"D015796","reg":"0"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":null,"s2_open_access_landing_url":null,"s2_open_access_license":null,"s2_open_access_status":null,"pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Axial spondyloarthritis manifests as a chronic inflammatory disease primarily affecting the sacroiliac joints and spine. Although chronic back pain and spinal stiffness are typical initial symptoms, peripheral (ie, enthesitis, arthritis, and dactylitis) and extra-musculoskeletal (ie, uveitis, inflammatory bowel disease, and psoriasis) manifestations are also common. Timely and accurate diagnosis is challenging and relies on identifying a clinical pattern with a combination of clinical, laboratory (HLA-B27 positivity), and imaging findings (eg, structural damage on pelvic radiographs and bone marrow oedema on MRI of the sacroiliac joints). The Assessment in SpondyloArthritis international Society classification criteria for axial spondyloarthritis are widely used for research and have contributed to a better understanding of the gestalt of axial spondyloarthritis. Persistent disease activity, assessed mainly by the Axial Spondyloarthritis Disease Activity Score, leads to irreversible structural damage and functional impairment. Management involves non-pharmacological (eg, education, smoking cessation, exercise, physiotherapy) and pharmacological therapy. Non-steroidal anti-inflammatory drugs remain first line pharmacotherapy, while tumour necrosis factor, IL-17, and Janus kinase inhibitors are considered second-line therapies. Future advances are expected to increase disease awareness, facilitate early and accurate diagnosis, optimise disease management, and enhance overall quality of life in patients with axial spondyloarthritis.","claims":[{"public_id":"cl_d3cc3153d55760aabc79d67c4bf5daa1","status":"active","text":"Non-steroidal anti-inflammatory drugs remain first-line pharmacotherapy, while tumour necrosis factor, IL-17, and Janus kinase inhibitors are considered second-line therapies.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_d3cc3153d55760aabc79d67c4bf5daa1"},{"public_id":"cl_7f3c6a8b67bdd72be9f4bc8eed39b8a1","status":"active","text":"Persistent disease activity leads to irreversible structural damage and functional impairment.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_7f3c6a8b67bdd72be9f4bc8eed39b8a1"},{"public_id":"cl_c6251a3631be7781a287c5c6385e0645","status":"active","text":"The Assessment in SpondyloArthritis international Society classification criteria for axial spondyloarthritis are widely used for research and have improved understanding of the disease gestalt.","confidence":0.94,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_c6251a3631be7781a287c5c6385e0645"},{"public_id":"cl_007810ca5c264247624eb72eb9642cd9","status":"active","text":"Timely and accurate diagnosis of axial spondyloarthritis is challenging and depends on a combination of clinical, laboratory, and imaging findings.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_007810ca5c264247624eb72eb9642cd9"}],"concepts":[{"public_id":"co_1cc31ca8afa5faa5d6ba3c708b5cfa17","status":"active","name":"HLA-B27 positivity","description":"Presence of the HLA-B27 laboratory marker used in diagnosis.","types":["laboratory finding"],"aliases":["HLA-B27"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_1cc31ca8afa5faa5d6ba3c708b5cfa17"},{"public_id":"co_2667354e743ae80a8bf4c2166b2a660e","status":"active","name":"imaging findings","description":"Radiographic or MRI features used to support diagnosis.","types":["diagnostic feature"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_2667354e743ae80a8bf4c2166b2a660e"},{"public_id":"co_26a8aeb00f34a9c5c4adc354aea2e737","status":"active","name":"Assessment in SpondyloArthritis international Society classification criteria","description":"Classification criteria used in research for axial spondyloarthritis.","types":["classification criteria"],"aliases":["ASAS classification criteria"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_26a8aeb00f34a9c5c4adc354aea2e737"},{"public_id":"co_2a60f9b4b388a4e9e1eca4e5916359e5","status":"active","name":"tumour necrosis factor inhibitors","description":"Biologic drugs that block tumour necrosis factor signaling.","types":["drug class"],"aliases":["TNF inhibitors","TNF"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_2a60f9b4b388a4e9e1eca4e5916359e5"},{"public_id":"co_376c9bbf6de60e3741cede6b4b3822fc","status":"active","name":"spine","description":"The vertebral column affected by inflammation in this disease.","types":["anatomical structure"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_376c9bbf6de60e3741cede6b4b3822fc"},{"public_id":"co_622452d48b0e9c72ccfde8e252cc0375","status":"active","name":"persistent disease activity","description":"Ongoing inflammatory activity over time in axial spondyloarthritis.","types":["disease state"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_622452d48b0e9c72ccfde8e252cc0375"},{"public_id":"co_669cfc07b10cb1898dc40cc13e65c93a","status":"active","name":"clinical pattern","description":"A combination of symptoms and signs used to recognize the disease.","types":["diagnostic feature"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_669cfc07b10cb1898dc40cc13e65c93a"},{"public_id":"co_72a445874fd3928c7c19b2cf5b81e96d","status":"active","name":"sacroiliac joints","description":"The joints connecting the sacrum to the iliac bones in the pelvis.","types":["anatomical structure"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_72a445874fd3928c7c19b2cf5b81e96d"},{"public_id":"co_74534dc8876e762d02f9745639045099","status":"active","name":"IL-17 inhibitors","description":"Drugs that inhibit interleukin-17 signaling.","types":["drug class"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_74534dc8876e762d02f9745639045099"},{"public_id":"co_82145aaa71e91602d5aa1c6776374ab2","status":"active","name":"non-steroidal anti-inflammatory drugs","description":"Anti-inflammatory medications used as first-line pharmacotherapy.","types":["drug class"],"aliases":["NSAIDs"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_82145aaa71e91602d5aa1c6776374ab2"},{"public_id":"co_8b9a7ec628ffffcaae9804078935bb2b","status":"active","name":"Janus kinase inhibitors","description":"Drugs that inhibit Janus kinase signaling pathways.","types":["drug class"],"aliases":["JAK inhibitors"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_8b9a7ec628ffffcaae9804078935bb2b"},{"public_id":"co_da63ab94a7c3f580252a529746ad1fb6","status":"active","name":"functional impairment","description":"Loss or reduction of physical function caused by disease.","types":["outcome"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_da63ab94a7c3f580252a529746ad1fb6"},{"public_id":"co_dccfc974821086594ddf658ad2ce28b3","status":"active","name":"Axial SpondyloArthritis Disease Activity Score","description":"A score used mainly to assess disease activity in axial spondyloarthritis.","types":["outcome measure"],"aliases":["ASDAS"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_dccfc974821086594ddf658ad2ce28b3"},{"public_id":"co_e2eadbeced88ef806e989c76a65cd4e1","status":"active","name":"axial spondyloarthritis","description":"A chronic inflammatory disease primarily affecting the sacroiliac joints and spine.","types":["condition"],"aliases":["axSpA"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_e2eadbeced88ef806e989c76a65cd4e1"}],"external_ids":{"DOI":"10.1016/s0140-6736(24)02263-3","ArXiv":null,"PubMed":39798984,"PubMedCentral":null,"MAG":null,"DBLP":null,"ACL":null},"open_access":{"is_open_access":false,"pdf_url":null,"landing_url":"https://sah.borca.ai/papers/275406579","source":null,"pdf_url_source":null,"license":null,"reason":"pdf_url_not_indexed"},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":632147,"paper_uid":"5a97b1a3-b058-4090-b8da-d9e237a8caae","canonical_identity":{"paper_id":632147,"paper_uid":"5a97b1a3-b058-4090-b8da-d9e237a8caae","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/275406579"}